The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2–advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy.
 
Jose Angel Garcia Saenz
No Relationships to Disclose
 
Manuel Ramos Vazquez
No Relationships to Disclose
 
Miguel Martin
Consulting or Advisory Role - Amgen; Lilly; Novartis; Pfizer; Roche/Genentech
Research Funding - Novartis (Inst)
 
Amparo Ruiz
No Relationships to Disclose
 
Serafin Morales
No Relationships to Disclose
 
Begona Bermejo
No Relationships to Disclose
 
Isabel Ruiz
No Relationships to Disclose
 
Ricardo Cubedo
No Relationships to Disclose
 
Luis De la Cruz Merino
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche
Research Funding - Celgene; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche
 
Antonio Anton
No Relationships to Disclose
 
Eva Maria Carrasco
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche Pharma AG (I)
Speakers' Bureau - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche Pharma AG (I)
Research Funding - AstraZeneca Spain (Inst); AstraZeneca Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genomic Health (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - PAM 50 taxane predictor
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche
 
Michelle Kneissl
Employment - Millennium
Stock and Other Ownership Interests - Millennium
 
Fabian Zohren
No Relationships to Disclose
 
Noelia Martinez
No Relationships to Disclose